In a phase I study conducted in Seoul, South Korea, in 37 healthy adult volunteers, EL-22 demonstrated good safety and a tolerable profile.
A New Method of Myostatin Inhibition in Mice via Oral Administration of Lactobacillus casei Expressing Modified Myostatin Protein
AUG 2022
View Publication
